Clariane SECHIX:CLARIP 63 5-Year ROIIC % is 23.34 as of Dec. 2025. GuruFocus rates CHIX:CLARIP with a GF Score™ of 63/100 and a GF Value™ of €2.47 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 534 Healthcare Providers & Services companies, Clariane SE ranks better than 80.34% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Clariane SE's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was 23.34%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Clariane SE's 5-Year ROIIC % or its related term are showing as below:
CHIX:CLARIp's 5-Year ROIIC % is ranked better than 80.34% of 534
companies
in the Healthcare Providers & Services industry
Industry Median: 3.33
vs CHIX:CLARIp: 23.34
Clariane SE (CHIX:CLARIp) 5-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Clariane SE 5-Year ROIIC % Related Terms
Clariane SE 5-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Clariane SE's 5-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CLARIP vs HCA, THC, DVA: 5-Year ROIIC % Comparison
For the Medical Care Facilities subindustry, Clariane SE's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clariane SE 5-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Clariane SE's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Clariane SE's 5-Year ROIIC % falls into.
Clariane SE's 5-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( 283.846 (Dec. 2025) - 129.151176 (Dec. 2020) )
/
( 13715.551 (Dec. 2025) - 13052.854 (Dec. 2020) )
=
154.694824
/
662.697
=
23.34%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Clariane SE (CHIX:CLARIP) has a 5-Year ROIIC % of 23.34 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Clariane SE and its competitors. According to the industry distribution chart, Clariane SE ranks #105 out of 534 companies in the Healthcare Providers & Services industry, placing it in the top 19.7%.
Is Clariane SE's 5-Year ROIIC % too high?
Clariane SE's current 5-Year ROIIC % is 23.34. The Healthcare Providers & Services industry median 5-Year ROIIC % is 3.33. Clariane SE's value of 23.34 is 600.9% above this industry median. Based on the distribution chart, Clariane SE ranks #105 out of 534 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Clariane SE has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Clariane SE's 5-Year ROIIC % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Clariane SE ranks #105 out of 534 companies for 5-Year ROIIC %. This places Clariane SE in the top 20% of its industry — outperforming the majority of peers. The industry median 5-Year ROIIC % is 3.33. Clariane SE's value of 23.34 is 600.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Healthcare Providers & Services company?
The median 5-Year ROIIC % among Healthcare Providers & Services companies is 3.33, based on 534 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clariane SE's current 5-Year ROIIC % of 23.34 is 600.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Clariane SE and its competitors. For the Healthcare Providers & Services industry, the median 5-Year ROIIC % is 3.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clariane SE's current 5-Year ROIIC % is 23.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clariane SE stock overvalued right now?
Based on GuruFocus' analysis, Clariane SE (CHIX:CLARIP) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.47, compared to a current price of €4.13 — trading 67% above its estimated fair value. The current 5-Year ROIIC % is 23.34 and 600.9% above the Healthcare Providers & Services industry median of 3.33. Clariane SE's overall GF Score™ is 63/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Clariane SE (CHIX:CLARIP), the current 5-Year ROIIC % is 23.34 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clariane SE (CHIX:CLARIP) Overvalued in 2026?
Based on GuruFocus' analysis, Clariane SE stock appears to be overvalued.
The current stock price of €4.13 is trading 67% above its estimated GF Value™ of €2.47.
GuruFocus considers Clariane SE to be Significantly Overvalued.
Key valuation signals for CHIX:CLARIP:
5-Year ROIIC %: 23.34
GF Value™: €2.47 vs. price of €4.13 (67% above fair value)
Industry Position: 600.9% above the Healthcare Providers & Services median (#105 of 534)
No single metric tells the full story. See the CHIX:CLARIP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clariane SE is a specialist in non-acute care and operates in two main areas: long-term care, through two forms of support, medicalized nursing homes offering specialty facilities accommodation and care for vulnerable older people and alternative living solutions, and specialty care activities such as specialty and post-acute , mental health and a number of medical, surgical and obstetrics clinics. Its segments include France, Germany, Benelux, Italy and Spain.
63GF Score
Get the complete analysis for CHIX:CLARIP
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CLARIP has been successfully added to your 
